MedTrace Logo

Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients

NCT01399957 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2015-11-10

No results posted yet for this study

Summary

Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.

Conditions

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • Acorda Therapeutics

    collaborator INDUSTRY

  • Mount Sinai Rehabilitation Hospital

    lead OTHER

Principal Investigators

  • Albert Lo, M.D, Ph.D. · Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital

  • Elizabeth Triche, Ph.D · Brown University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2014-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01399957 on ClinicalTrials.gov